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ABSTRACT 
The cluster of lipid abnormalities associated with type 2 diabetes is defined by increases in triglyceride (TG) 
and small, dense low-density lipoprotein (LDL) concentrations and decreases in high-density lipoprotein 
(HDL) cholesterol. Plasma LDL cholesterol levels are generally normal because the increase in the number 
of small, dense LDL particles is accompanied by a reduction in large LDL particles. Each of the features of 
diabetic dyslipidemia has been associated with increased risk of cardiovascular disease, the leading cause of 
death in type 2 diabetics.   Increasing evidence in both experimental and clinical studies suggests that 
oxidative stress plays a major role in the pathogenesis of both types of diabetes mellitus. Free radicals are 
formed disproportionately in diabetes by glucose oxidation, nonenzymatic glycation of proteins, and the 
subsequent oxidative degradation of glycated proteins. Abnormally high levels of free radicals and the 
simultaneous decline of antioxidant defense mechanisms can lead to damage of cellular organelles and 
enzymes, increased lipid peroxidation, and development of insulin resistance. These consequences of 
oxidative stress can promote the development of complications of diabetes mellitus. Changes in oxidative 
stress biomarkers, including superoxide dismutase, catalase, glutathione reductase, glutathione peroxidase, 
glutathione levels, vitamins, lipid peroxidation, nitrite concentration, nonenzymatic glycosylated proteins, 
and hyperglycemia in diabetes, and their consequences, are discussed in this review. In vivo studies of the 
effects of various conventional and alternative drugs on these biomarkers are surveyed. There is a need to 
continue to explore the relationship between free radicals, diabetes, and its complications, and to elucidate 
the mechanisms by which increased oxidative stress accelerates the development of diabetic complications, 
in an effort to expand treatment options. 
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INTRODUCTION 
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia and insufficiency of secretion or 
action of endogenous insulin. Although the etiology  of this disease is not well defined, viral infection, 
autoimmune disease, and environmental factors have been implicated
1–5. While exogenous insulin and other 
medications can control many aspects of diabetes, numerous complications affecting the vascular system, 
kidney, retina, lens, peripheral nerves, and skin are common and are extremely costly in terms of longevity 
and quality of life.  Increased oxidative stress is a widely accepted participant  in the development and 
progression of diabetes and its complications
6–8. Diabetes is usually accompanied by increased production of 
free radicals
7–10 or impaired antioxidant defenses
11–13. Mechanisms by which increased oxidative stress is 
involved in the  diabetic complications are partly known, including activation  of transcription factors, 
advanced glycated end products (AGEs), and protein kinase C. This review focuses on recent experimental 
studies of diabetes and drug interventions done within the context of in vivo assay systems. There are also 
myriad in vitro experiments and clinical studies which deserve a review of their own. 
Each of the features  of diabetic dyslipidemia has been associated with increased risk of  cardiovascular 
disease, the leading cause of death in type 2 diabetics.  Although attempts at decreasing cardiovascular 
disease morbidity and mortality have usually been focused on lowering LDL cholesterol, it is important to 
consider other features of the abnormal lipid profile typical of type 2 diabetes that may contribute to the 
disease process, particularly TG rich remnants and small, dense LDL. These factors are not detected by 
standard lipid testing, but part of the benefits observed in coronary artery disease-prevention trials may be 
because of improvements of these parameters. The cluster of lipid abnormalities associated with type 2 
diabetes is  defined by increases in triglyceride (TG) and small, dense low-density  lipoprotein (LDL) 
concentrations and decreases in high-density lipoprotein (HDL) cholesterol. Plasma LDL cholesterol levels 
are generally normal because the increase in the number of small, dense LDL particles is accompanied by a 
reduction in large LDL particle
14. 
Importantly, insulin resistance and type 2 diabetes often occur along with other metabolic abnormalities such 
as obesity, hypertension, and hypercoagulability This grouping of abnormalities has been referred to as the 
metabolic syndrome or ‘‘syndrome X’’ and has been associated with an increased risk for atherosclerosis
15,16. 
Other abnormalities may be associated  with poorly controlled diabetes, for example, glycosylation of 
lipoproteins and other proteins involved in lipoprotein metabolism. 
 
OXIDATIVE STREES IN DIABETES MELLITUS 
Oxidative stress depicts the existence of products called free radicals and reactive oxygen species (ROS) 
which are formed under normal physiological conditions but become deleterious when not being quenched 
by the antioxidant systems
17. There are convincing experimental and clinical evidences that the generation of 
reactive oxygen species is increased in both types of diabetes and that the onset of diabetes is closely 
associated with oxidative stress
18,19. Free radicals are formed disproportionately in diabetes by glucose 
autoxidation, polyol pathway and non-enzymatic glycation of proteins
20. Abnormally high levels of free 
radicals and simultaneous decline of antioxidant defense systems can lead to the damage of cellular 
organelles and enzymes, increased lipid peroxidation and development of complications of  diabetes 
mellitus
21. Free radicals may play an important role in the causation and complications of diabetes mellitus
22. 
In diabetes mellitus, alterations in the endogenous free radical scavenging defense mechanisms may lead to 
ineffective scavenging of reactive oxygen species, resulting in oxidative damage and tissue injury. Oxidative 
stress is currently suggested as  mechanism  underlying diabetes and diabetic complications
23. Enhanced 
oxidative stress and changes in antioxidant capacity, observed in both clinical and experimental diabetes 
mellitus, are thought to be the etiology of chronic diabetic complications 
24
In recent years, much attention has been focused on the role of oxidative stress, and it has been reported that 
oxidative stress may constitute the key and common event in the pathogenesis of secondary diabetic 
complications
. 
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and interaction with environmental stimuli. Oxidative stress results from an imbalance between radical-
generating and radical-scavenging systems, i.e. increased free radical production or reduced activity of 
antioxidant defenses or both. Implication of oxidative stress in the pathogenesis of diabetes is suggested, not 
only by oxygen free-radical generation, but also due to nonenzymatic protein glycosylation, auto-oxidation of 
glucose
26, impaired glutathione metabolism
27, alteration in antioxidant enzymes
28, lipid peroxides formation 
and decreased ascorbic acid levels
29. In addition to GSH, there are other defense mechanisms against free 
radicals like the enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) 
whose activities contribute to eliminate superoxide, hydrogen peroxide and Hydroxyl radical
30. The level of 
these antioxidant enzymes critically influences the susceptibility of various tissues to oxidative stress and is 
associated with the development of complications in diabetes. Also this is particularly relevant and dangerous 
for the beta islet, which is among those tissues that have the lowest levels of intrinsic antioxidant defenses
31, 
32, 33,34.  
 
BIOMARKERS OF OXIDATIVE STRESS 
Lipid Peroxidation 
Diabetes produces disturbances of lipid profiles, especially an increased susceptibility to lipid peroxidation
35, 
which is responsible for increased incidence of atherosclerosis
36, a major complication of diabetes mellitus
37. 
An enhanced oxidative stress has been observed in these patients as indicated by increased  free radical 
production
38, lipid peroxidation and diminished antioxidant status. Hydroperoxides have toxic effects on cells 
both directly and through degradation to highly toxic hydroxyl radicals. They may also react with transition 
metals like iron or copper to form stable aldehydes such as malondialdehydes that will damage cell 
membranes. Peroxyl radicals can remove hydrogen from lipids, producing  hydroperoxides that further 
propagate the free-radical pathway
39. 
 
Glutathione Peroxidase and Glutathione Reductase 
Recent studies of the effects of various antioxidants on glutathione concentrations found that glutathiobne are 
decreased in the liver
40, kidney
41, pancreas
42, plasma, red blood cells
43, nerve, and precataractous lens
44 of 
chemically induced diabetic animals.  However, there is also some contradictory evidence  of increased 
glutathione concentration in diabetic  rat kidney and lens
45.  Levels of glutathione are reported to be 
normalized by vanadyl, dehydroepiandrosterone (DHEA), oil of Eruca sativa seeds, nicotinamide, L-arginine 
or nitroprusside
46, melatonin, and melatonin plus desferrioxamine, when these antioxidants are given prior to 
or at the same time as the diabetogen. However, antioxidants that fail to reverse the effects of established 
diabetes on glutathione levels include coenzyme Q10, quercetin, piperine, isoeugenol, DHEA, melatonin
47, 
and taurine.  
 
Catalase 
Catalase, located in peroxisomes, decomposes hydrogen peroxide to water and oxygen. Catalase activity is 
consistently found to be elevated in heart and aorta, as well as brain of diabetic rats. In contrast to decreased 
renal, hepatic and red blood cell catalase activity, in liver and kidney of diabetic animals is increased
48. 
These alterations of catalase activity due to diabetes  are normalized by treatment with captopril, 
aminoguanidine, melatonin (in liver), acetylsalicylic acid, DHEA, probucol, lipoic acid, and stobadine, all of 
which were administered before or at the same time as the diabetogen. By contrast, treatment of established 
diabetes of 4 weeks or more does not reverse or normalize diabetic effects. For example, no reversals are 
seen after treatment  with melatonin, quercetin, coenzymeQ10, piperine, isoeugenol,  gemfibrozil, or 
combined vitamin C, vitamin E, and carotene
49. Finally, effects of diabetes on cardiac catalase activity are 
exacerbated by treatment with quercetin
50 or coenzyme Q10 . 
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Superoxide Dismutase (SOD) 
SOD converts superoxide anion radicals produced in the body to hydrogen peroxide, thereby reducing the 
likelihood of superoxide anion interacting with nitric oxide to form reactive peroxynitrite. The effect of 
diabetes on the activity of SOD is erratic, with no discernable pattern based on gender or species of animal, 
or duration of diabetes, or tissue studied. Renal activity, for example, is within normal levels at 3 and 6 
weeks after STZ, lower than normal at 6 weeks post-STZ, but also elevated after 6 or 12 weeks of diabetes
51. 
In liver, SOD activity is depressed by the third or fourth week of diabetes, but is either normal or elevated 8 
weeks after STZ. Kaul et al. found cardiac SOD activity decreased after 4 or 8 weeks of diabetes, but Stefek 
et al. reported elevated cardiac activity at 32 weeks, and activity in aorta seems to be unaffected by diabetes. 
Likewise, activity may be elevated or decreased in red blood cells, decreased in retina and plasma, and 
increased in pancreas.  Alterations of SOD activity in diabetic animals are  normalized by probucol, 
captopril
52, DHEA, lipoic acid, melatonin, boldine,  nitecapone, and stobadine , all of which were 
administered prior to or concomitant with the diabetogen. When treatment is initiated in animals with well 
established diabetes, coenzyme Q10 and piperine normalize renal activity, but no reversal of diabetic effects 
is seen with melatonin, aminoguanidine  or desferrioxamine, or gemfibrozil.  Treatment with vitamin C, 
vitamin E, and beta carotene for 8 weeks elevates hepatic SOD activity in diabetic rats, which is normal 
without treatment
53.  
 
Vitamins 
Vitamin E, a component of the total peroxyl radical-trapping antioxidant system, reacts directly with peroxyl 
and superoxide radicals and singlet oxygen and protects membranes from lipid peroxidation. The deficiency 
of vitamin E is concurrent  with increased peroxides and aldehydes in many tissues.  There have been 
conflicting reports about vitamin E levels in diabetic animals and human subjects. Plasma and/or tissue levels 
of vitamin E are reported to be unaltered, increased, or decreased
54 by diabetes. Discrepancies among studies 
in terms of preventive or deleterious effects of vitamin E on diabetes induced vascular aberrations may arise 
from the variety of examined blood vessels or the administered dose of vitamin E.  
 
Nitrite Level 
Increased oxidative stress and subsequent activation of the transcription factor NF-kappa B have been linked 
to the development of late diabetic complications. NF-kappa B enhances nitric oxide production, which is 
believed to be a mediator of islet beta-cell damage. Nitric oxide may react with superoxide anion radical to 
form reactive peroxyl nitrite radicals. A number of studies are continuing to examine the role of nitric oxide 
in diabetes mellitus. For example, subnormal hepatic nitric oxide concentrations in STZ-diabetic rats are 
restored after melatonin treatment to levels significantly higher than normal. And, although elevated levels of 
nitric oxide levels in kidneys of 3 week diabetic rats are further enhanced by  S-methyl-L-thiocitrulline 
treatment, administration of losartan along with S-L-thiocitrulline for 3–5 weeks normalizes the nitric oxide 
levels implying that angiotensin II is an important modulator of nitric oxide pathway in diabetes
55. On the 
other hand, nitric oxide levels in plasma are decreased in alloxan-diabetic rats, an effect that can be abrogated 
by prior and simultaneous administration of L-arginine, a precursor of nitric oxide
56
Resistance to insulin may contribute to the atherogenic dyslipidemia of diabetes by increasing the hepatic 
secretion of very low-density lipoprotein (VLDL). Metabolic tracer studies have documented overproduction 
of VLDL TG in insulin-resistant patients with hypertriglyceridemia
.  
 
DIABETIC DYSLIPIDEMIA 
Association of Insulin Resistance and Hepatic Very Low-Density Lipoprotein Secretion 
57. Additionally, several recent studies 
demonstrate increased secretion of apolipoprotein (apo) B in type 2 diabetes
58. The increased secretion of 
apoB-containing lipoprotein particles may be the result of increased free fatty acid (FFA) flux to the liver
59. 
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apoB secretion
60. This resistance to insulin may be at the level of the regulation of apoB degradation or 
inhibition of microsomal triglyceride transfer protein activity, a protein identified as a key component of the 
VLDL assembly process
61.  Because of increased endogenous secretion of apoB-containing lipoprotein 
particles, the increased plasma levels of TG can drive a metabolic process that results in reduced HDL 
cholesterol levels and LDL particles  that are smaller and more  dense. In a substrate-driven reaction, 
cholesterol ester transfer protein (CETP) exchanges VLDL TG for HDL cholesterol. TG-rich HDL particles 
are hydrolyzed by hepatic lipase (HL) and, as a result, are rapidly catabolized and cleared from plasma
62. 
HDL particles are heterogeneous and are classified by particle sizes that range from small, dense HDL3 to 
larger HDL2 particles
63. Typically, the  reduced plasma levels of HDL in patients with type 2 diabetes 
manifest as  reductions in the HDL2 subspecies with relative or absolute increases in  HDL3.  Increased 
concentrations of VLDL in plasma also result in the increased production of small, dense LDL particles. As 
many as seven distinct LDL subspecies, which differ in metabolic behavior and pathologic roles, have been 
identified (Fig. 1) 
[64]. Plasma VLDL levels correlate positively with increased density and decreased size of 
LDL, and increased concentrations of small, dense LDL in turn have been shown to be associated with 
reduced plasma HDL levels. Importantly, the residence  time of small, dense LDL in plasma may be 
prolonged, given their relatively reduced affinity for the LDL receptor
64.  
 
Effects of Insulin Resistance on Lipid and Lipoprotein Clearance 
Impaired clearance of lipid and lipoprotein particles represents another  important mechanism by which 
insulin resistance can lead to abnormal lipid profiles. Insulin resistance has been associated with impaired 
lipoprotein lipase (LPL) and increased HL activity
65. LPL is synthesized in muscle and adipose tissue and 
interacts with TG-rich lipoproteins in capillary endothelial cell beds where it hydrolyzes TG into FFA. The 
resultant lipoprotein particles are reduced in core volume and surface and are either cleared through remnant 
removal pathways or moved along the delipidation pathway where they are converted into less buoyant LDL 
particles. HL is responsible for the hydrolysis of phospholipids in LDL and HDL particles; its increased 
activity in the setting of insulin resistance has been associated with smaller and denser LDL particles and a 
decrease in HDL2 particles because the latter are more rapidly cleared from plasma. Lipid effects on insulin 
sensitivity Insulin resistance and type 2 diabetes mellitus are often characterized by increased plasma FFA 
concentrations because of increased adipose tissue  efflux or impaired insulin-mediated skeletal muscle 
uptake
66. The fact that FFA levels are elevated in individuals with impaired glucose tolerance suggests that 
insulin resistance associated with increased FFA levels occurs before the onset of hyperglycemia. Elevations 
of plasma FFA concentrations may interfere with glucose metabolism by impairing glucose uptake and by 
use in muscle
67. In addition, infusion of lipid emulsions and heparin to increase ambient FFA concentrations 
has been shown to increase gluconeogenesis in patients with insulin resistance and type 2 diabetes; however, 
glycogenolysis was  simultaneously dampened in these patients so that net glucose production  remained 
unchanged. Increased FFA concentrations in plasma may also impair hepatic insulin extraction, thereby 
contributing to peripheral hyperinsulinemia in insulin resistance. At the level of the pancreatic b-cell, FFA 
acutely increases glucosestimulated insulin secretion, whereas chronic exposure has been associated with 
relatively impaired insulin secretion
68. Finally, in the presence of insulin resistance, FFA in the form of TG is 
deposited in muscle and the liver, heart, and pancreas where it may impair organ function. Notably, agents 
that lower elevated FFA, such as the thiazolidinediones (TZDs), have  been shown to improve insulin 
sensitivity in muscle, liver, and adipose tissue
69
STZ-  or alloxan-induced diabetes in rats represents  well-established animal models of type 1 insulin 
dependent, diabetes mellitus. Increased production of high levels of oxygen free radicals has been linked to 
glucose oxidation and nonenzymatic glycation of proteins which contribute to the development of diabetic 
complications. Protective effects of exogenously administered antioxidants have been extensively studied in 
animal models within recent years, thus providing some insight into the relationship between free radicals, 
. 
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diabetes, and its complications. In vitro and clinical studies may provide additional useful ways to probe the 
interconnections of oxidant stress and diabetes, and there is a need to continue to explore the mechanisms by 
which increased oxidative stress accelerates the development of complications in diabetes.  
Abnormal lipid metabolism often presents in patients with type 2 diabetes. Resistance to insulin likely 
underlies the changes that occur in lipid parameters. Increased FFA vailability can drive the secretion of TG 
rich lipoproteins from the liver, and this increased TG substrate can lead to reductions in HDL cholesterol as 
well as the conversion of LDL particles into particles that are smaller and denser. The combination of 
elevated TG, reduced HDL cholesterol, and smaller and denser LDL particles typifies the dyslipidemia 
associated with type 2 diabetes and insulin resistance. Each of these lipid changes has been independently 
associated with increased cardiovascular disease risk. A variety of treatment options exist, and changes in 
lifestyle and behaviors known to adversely alter lipid metabolism should be key components of any program 
designed to manage atherogenic  dyslipidemia. Effective pharmacologic therapies include lipid-lowering 
agents, such as statins, fibrates, and niacin, as well as antidiabetic agents, such as the thiazolidinediones and 
metformin. Treatment with these agents  alone or in combination has been shown to correct the lipid 
abnormalities associated with type 2 diabetes and reduce the risk of cardiovascular disease.  
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Figure 1. Hypothetical metabolic scheme incorporating proposed pathways for the production of major LDL subclasses I, II, III, 
and IV. The properties of triglyceride-rich lipoproteins secreted by the liver are determined by the operation of multiple pathways 
(1 and 2) and by hepatic TG  availability. In pathway 1, triglyceride-rich VLDL-1 and triglyceride-poor IDL-2 particles are 
coordinately produced. VLDL-1 production results from a discrete quantity of lipid on a precursor particle. Lipolysis of VLDL-1 
yields remnants, which in turn yield LDL-III by hepatic lipase. Further remodeling of these particles may occur by CETP-mediated 
triglyceride enrichment and hepatic lipase-mediated lipolysis. Pathway 2, which results in the production of VLDL-2, is distinct 
from pathway 1 and gives rise to IDL-1 and LDL-II by lipolysis. Further processing by CETP-mediated transfer of triglycerides 
into LDL-II and lipolysis by hepatic lipase yields smaller and denser LDL products. CE, cholesteryl esters; LPL, lipoprotein lipase. 
(From Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363–79; 
with permission.) 
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